论文部分内容阅读
作者以心肌梗塞急性期住院患者为对象,对其尿中抗凝血酶Ⅲ(ATⅢ)的浓度进行了测定,并对心肌梗塞急性期经冠状动脉内血栓溶解疗法治疗的患者也进行了对比检测研究。结果:正常人尿中ATⅢ浓度为33.7±14.4μg/day,心肌梗塞急性期患者尿中ATⅢ浓度为610.8±321.4μg/day,后者显著高于前者,心肌梗塞慢性期患者尿中ATⅢ浓度为77.5±40.3μg/day,已较急性期明显减少。心肌梗塞急性期的重症程度按Killip 分类,其中重型患者尿中ATⅢ的排泄量显著增加。经冠状动脉内血栓溶解疗法治疗早期成功的病例,尽管其CPK、LDH 值上升显著,但尿中ATⅢ的排泄量没
The author of acute myocardial infarction inpatients as the object, its urinary antithrombin Ⅲ (AT Ⅲ) concentration was measured and the acute myocardial infarction patients treated by coronary thrombolysis were also compared the study. Results: The concentration of ATⅢ in urine of normal people was 33.7 ± 14.4μg / day. The concentration of ATⅢ in urine of patients with acute myocardial infarction was 610.8 ± 321.4μg / day, which was significantly higher than the former. The concentration of ATⅢ in urine of patients with chronic myocardial infarction was 77.5 ± 40.3μg / day, significantly lower than the acute phase. The severity of acute myocardial infarction was categorized by Killip, with a significant increase in excretion of AT III in the urine of critically ill patients. In the early successful treatment of coronary thrombolytic therapy, despite its CPK, LDH value increased significantly, but the urinary excretion of AT Ⅲ did not